New 8-Week Treatment Approved for All Hepatitis C Genotypes

By Kelly Young

Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH

The FDA has approved the first 8-week treatment for chronic hepatitis C genotypes 1 through 6 in patients with mild or no cirrhosis.

Mavyret, a combination of glecaprevir and pibrentasvir, is also approved for patients with renal impairment and adults with HCV genotype 1 infection who've been treated with either an NS5A inhibitor or an NS3/4A protease inhibitor.

In clinical trials, 92-100% of patients treated with Mavyret for 8, 12, or 16 weeks had no detectable viral levels 12 weeks post-treatment.

Common adverse reactions included fatigue, headache, and nausea. Clinicians should screen patients for prior or current hepatitis B infection before starting treatment as some coinfected patients have reported HBV reactivation after taking HCV direct-acting antivirals.

Mavyret is contraindicated in patients with severe cirrhosis and those taking atazanavir and rifampin.